Status In progress
Process STA 2018
ID number 1647

Provisional Schedule

Committee meeting 11 May 2021
Expected publication 21 July 2021

Project Team

Project lead Kate Moore

Email enquiries

Evidence Review Group / Assessment Group Warwick Evidence, Warwick Medical School, University of Warwick

Consultees

Companies sponsors Novartis (inclisiran)
Others Department of Health and Social Care
  NHS Bradford City CCG
  NHS Eastern Cheshire CCG
  NHS England
  Welsh Government
Patient carer groups BEMDA: Black and Ethnic Minority Diabetes Association
  Black Health Agency for Equality
  Blood Pressure UK
  British Cardiac Patients Association
  Cardiovascular Care Partnership
  Diabetes Research and Wellness Foundation
  Diabetes UK
  Genetic Alliance UK
  HEART UK
  InDependent Diabetes Trust
  JDRF
  Network of Sikh Organisations
  Pulmonary Hypertension Association UK
  Pumping Marvellous Foundation
  South Asian Health Foundation
  Specialised Healthcare Alliance
  The Somerville Foundation
Professional groups Association of Genetic Nurses & Counsellors
  British and Irish Hypertension Society
  British Association for Nursing in Cardiovascular Care
  British Atherosclerosis Society
  British Cardiovascular Intervention Society
  British Cardiovascular Society
  British Dietetic Association
  British Geriatrics Society
  British Heart Foundation
  British Heart Rhythm Society
  British Inherited Metabolic Disease Group
  British Nuclear Cardiology Society
  British Society for Gene and Cell Therapy
  British Society for Genetic Medicine
  British Society for Haematology
  British Society for Haemostasis and Thrombosis
  British Society for Heart Failure
  British Society for Human Genetics
  British Society of Cardiovascular Imaging
  Clinical Leaders of Thrombosis
  National Heart and Lung Institute
  Primary Care Cardiovascular Society
  Royal College of Emergency Medicine
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society for Cardiological Science & Technology
  Society for Endocrinology
  Society for Vascular Nurses
  Society for Vascular Technology
  TREND UK
  UK Clinical Pharmacy Association
  UK Genetic Testing Network
  Vascular Society of Great Britain & Ireland

Commentators

Associated public health groups Public Health England
  Public Health Wales
Comparator companies Accord Healthcare UK (atorvastatin, ezetimibe, fluvastatin, pravastatin, rosuvastatin, simvastatin)
  Advanz Pharma (ezetimibe)
  Amgen UK (evolocumab)
  Aspire Pharma (fluvastatin)
  AstraZeneca UK (rosuvastatin)
  Aurobindo Pharma (atorvastatin, ezetimibe, pravastatin, rosuvastatin, simvastatin)
  Brown and Burk UK (simvastatin)
  Consilient Health (atorvastatin, rosuvastatin)
  Daiichi Sankyo UK (bempedoic acid)
  Dexcel Pharma (atorvastatin)
  Flamingo Pharma UK (atorvastatin)
  Glenmark Pharmaceuticals (ezetimibe, rosuvastatin)
  Lupin Pharmaceuticals (simvastatin)
  Merck Sharp & Dohme (ezetimibe, simvastatin)
  Mylan UK (atorvastatin, ezetimibe, fluvastatin, pravastatin, rosuvastatin)
  Novartis Pharmaceuticals UK (fluvastatin)
  Pfizer (atorvastatin)
  Rosemont Pharmaceuticals (simvastatin)
  Sandoz (ezetimibe, fluvastatin, rosuvastatin, simvastatin)
  Sanofi (alirocumab)
  Sun Pharmaceuticals (atorvastatin, rosuvastatin)
  Wockhardt UK (atorvastatin)
  Zentiva UK (atorvastatin, ezetimibe, rosuvastatin)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Diabetes UK Cymru
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups British Society for Cardiovascular Research
  Cardiac and Cardiology Research Department, Barts
  Central Cardiac Audit Database
  Cochrane Cystic Fibrosis & Genetic Disorders Group
  Cochrane Heart Group
  Cochrane Hypertension Group
  Cochrane Metabolic & Endocrine Disorders Group
  Cochrane Stroke Group
  European Council for Cardiovascular Research
  Genomics England
  Heart Research UK
  MRC Clinical Trials Unit
  National Centre for Cardiovascular Preventions and Outcomes
  National Institute for Cardiovascular Preventions and Outcomes
  National Institute for Health Research
  The Circulation Foundation
  Wellcome Trust

Timeline

Key events during the development of the guidance:

Date Update
26 August 2020 Invitation to participate
26 August 2020 In progress. Invitation to participate
13 July 2020 - 10 August 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance